Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086067 | 0.83 | TSHR (0.39) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL26768116 | 0.80 | TP53 (0.36) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL27473825 | 0.80 | TP53 (0.36) | TSHRHSD17B10TP53MGAMGAA | |
| Hydrochloric Acid SCHEMBL30642222 | 0.78 | TP53 (0.35) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL9219469 | 0.70 | — | — | |
| SCHEMBL17233403 | 0.69 | TSHR (0.46) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL22478830 | 0.68 | CYP2C19 (0.53) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL4687488 | 0.68 | CYP3A4 (0.34) | TSHRHSD17B10TP53MGAMGAA | |
| SCHEMBL4689127 | 0.68 | TSHR (0.35) | TSHRHSD17B10TP53 | |
| SCHEMBL20134627 | 0.68 | TP53 (0.33) | TSHRHSD17B10TP53MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114889-B1 | METHOD OF PREPARING MONTELUKAST AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO LTD (KR) | 2014-01-22 | — | — | EP | disclosed |
| US-8217174-B2 | Method of preparing montelukast and intermediates used therein | HANMI HOLDINGS CO., LTD. (KR) | 2012-07-10 | — | — | US | disclosed |
| US-20100099876-A1 | METHOD OF PREPARING MONTELUKAST AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099876-A1 | METHOD OF PREPARING MONTELUKAST AND INTERMEDIATES USED THEREIN | LTC4S, LTB4R, LTB4R2 | TSHR 4179/4885HSD17B10 515/4885TP53 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.